|Systematic (IUPAC) name|
|Legal status||P (UK)|
|Mol. mass||420.427 g/mol|
| (what is this?)
Aminophylline is less potent and shorter-acting than theophylline. Its most common use is in the treatment of airway obstruction from asthma or COPD. It is used off-label as a reversal agent during nuclear stress testing. Aminophylline is a nonselective adenosine receptor antagonist and phosphodiesterase inhibitor.
It is more soluble in water than theophylline. White or slightly yellowish granules or powder, having a slight ammoniacal odor and a bitter taste. Upon exposure to air, it gradually loses ethylenediamine and absorbs carbon dioxide with the liberation of free theophylline. Its solutions are alkaline. One g dissolves in 25 mL of water to give a clear solution; 1 g dissolved in 5 mL of water crystallizes upon standing, but redissolves when a small amount of ethylenediamine is added. Insoluble in alcohol and in ether.
Mechanism of action
Like other methylated xanthine derivatives, aminophylline is both a
- competitive nonselective phosphodiesterase inhibitor  which raises intracellular cAMP, activates PKA, inhibits TNF-alpha  and leukotriene synthesis, and reduces inflammation and innate immunity and
- nonselective adenosine receptor antagonist.
Aminophylline causes bronchodilation, diuresis, central nervous system and cardiac stimulation, and gastric acid secretion by blocking phosphodiesterase which increases tissue concentrations of cyclic adenosine monophosphate (cAMP) which in turn promotes catecholamine stimulation of lipolysis, glycogenolysis, and gluconeogenesis, and induces release of epinephrine from adrenal medulla cells
Adenosine is an endogenous extracellular messenger that can regulate myocardial oxygen needs. It acts through cellular surface receptors which effect intracellular signalling pathways to increase coronary artery blood flow, slow heart rate, block atrioventricular node conduction, suppress cardiac automaticity, and decrease β-adrenergic effects on contractility. Adenosine also antagonizes chronotropic and ionotropic effects of circulating catecholamines. Overall, adenosine decreases the heart’s rate and force of contraction, which increases blood supply to the cardiac muscle. Given specific circumstances this mechanism (which is intended to protect the heart) may cause atropine-resistant refractory bradyasystole. Adenosine’s effects are concentration-dependent. Adenosine’s receptors are competitively antagonized by methylxanthines such as aminophylline. Aminophylline competitively antagonizes the cardiac actions of adenosine at the cell surface receptors. Thus, it increases heart rate and contractility.
Precautions, contraindications and interactions
Aminophylline has shown some promise as a bodyfat reducer when used as a topical cream (sometimes referred to as "cutting gel"). Aminophylline is also a treatment option for anaphylactic shock.
- Minomal R 175 mg tab
- Minomal R 350 mg tab
- Minomal SR 600 mg tab
- "Aminophylline Professional Monograph".
- Mader, TJ; Smithline HA, Durkin L, Scriver G (March 2003). "A randomized control trial of intravenous aminophylline for atropine-resistant out-of-hospital asystolic cardiac arrest". Academic Emergency Medical Journal 10 (3): 192–197. Retrieved 2012 Feb 10.
- Essayan DM. (2001). "Cyclic nucleotide phosphodiesterases.". J Allergy Clin Immunol. 108 (5): 671–80. doi:10.1067/mai.2001.119555. PMID 11692087.
- Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. (2008). "Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition". Clinics (Sao Paulo). 63 (3): 321–8. doi:10.1590/S1807-59322008000300006. PMC 2664230. PMID 18568240.
- Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (February 1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". Am. J. Respir. Crit. Care Med. 159 (2): 508–11. PMID 9927365.
- Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. (2005). "Leukotrienes: underappreciated mediators of innate immune responses". J Immunol. 174 (2): 589–94. PMID 15634873.
- Daly JW, Jacobson KA, Ukena D. (1987). "Adenosine receptors: development of selective agonists and antagonists". Prog Clin Biol Res. 230 (1): 41–632. PMID 3588607.
- Mader, TJ; Gibson, P (7). cws_home/505959/description#description "Adenosine receptor antagonism in refractory asystolic cardiac arrest: results of a human pilot study". Elsevier Resuscitation 35: 3–7. Retrieved 2012 Feb 10.
- Perouansky, M; Shamir M, Hershkowitz E, Donchin Y (12). portal.info.subzero.lib.uoguelph.ca/tmp/5676621964383762041.pdf "Successful resuscitation using aminophylline in refrectory cardiac arrest with asystole". Elsevier Resuscitation 38: 39–41. Retrieved 2012 Feb 16.
- Turan, A; Kasuya Y, Govinda R, Obal D, Rauch S, Dalton J, et al (February 2010). anesthesia-analgesia.org/ content/110/2/449 "The effect of aminophylline on loss of consciousness, bispectral index, propofol requirement, and minimum alveolar concentration of desflurane in volunteers". Anesthesia and Analgesia 110 (2): 449–454. Retrieved 2012 Feb 17.
- Luszczki, JJ; Jankiewicz K, Jankiewicz M, Czuczwar SJ (May 2007). portal.info.sub zero.lib.uoguelph.ca/detailssfx.xqy?uri=/0014299 9/v562i12/53_papio atmmesm.xml "Pharmacokinetic and pharmacodynamic interactions of aminophylline and topiramate in the mouse maximal electroshock-induced seizure model". European Journal of Pharmacology 562 (1-2): 53–59. Retrieved 2012 Feb 17.
- "Aminophylline in bradyasystolic cardiac arrest", Emerg Med J. 24 (8), 2007: 582–3, PMID 17652689
- Caruso MK, Pekarovic S, Raum WJ, Greenway F (May 2007). "Topical fat reduction from the waist". Diabetes, obesity & metabolism 9 (3): 300–3. doi:10.1111/j.1463-1326.2006.00600.x. PMID 17391155.
- Blackbourne LH. Surgical Recall. Lippincott Williams and Wilkins, 2009. pp169